REG - Adv Medical Solutns. - Notice of Interim Results

Advanced Medical SolutionsAnnouncement

17/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220817:nRSQ2421Wa&default-theme=true

RNS Number : 2421W  Advanced Medical Solutions Grp PLC  17 August 2022

17 August 2022

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Notice of Interim Results

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, will announce its
interim results for the six months ended 30 June 2022 on Wednesday, 14
September 2022.

 

A briefing for analysts will be held at 10am GMT on the day of the results.
For further information, please contact AMS@consilium-comms.com
(mailto:AMS@consilium-comms.com) .

 

- End -

 

 

 

For further information, please contact:

 

 Advanced Medical Solutions Group plc                Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 Consilium Strategic Communications                  Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Matthew Neal / Matthew Cole

 Investec Bank PLC (NOMAD & Broker)                  Tel: +44 (0) 20 7597 5970
 Daniel Adams / Gary Clarence

 HSBC Bank PLC (Broker)                              Tel: +44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

 

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made three acquisitions:
Sealantis, an Israeli medical device company with a patent-protected sealant
technology platform; Biomatlante, an established French developer and
manufacturer of innovative surgical biomaterial technologies and Raleigh, a UK
leading coater and converter of materials predominately for woundcare and
bio-diagnostics products.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Germany, France and Israel. Established in
1991, the Group has more than 700 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORKQLFFLVLEBBQ